Merck's sacituzumab tirumotecan meets both primary endpoints in the pivotal Phase 3 TroFuse-005 trial for advanced endometrial cancer, Relay Therapeutics reports the first clinical evidence of PI3Kα mutant-selective inhibition in PIK3CA-driven vascular anomalies in...
Why Neurology Clinical Trials Need Purpose-Built AI
Each year on May 20, International Clinical Trials Day recognizes James Lind’s 1747 scurvy trial and the patients, clinicians, coordinators, sponsors and researchers who make clinical progress possible. It is also a moment to look honestly at where clinical research...
What the Veppanu Approval Means for ESR1 Breast Cancer
The FDA's approval of Veppanu (vepdegestrant) marks the first regulatory clearance for a PROTAC in any disease area, and opens a new chapter in the treatment of ESR1-mutated advanced breast cancer. On 1 May 2026, the United States Food and Drug Administration approved...
Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis
Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...
Clinical Trials Roundup | 15 May 2026
AstraZeneca's eneboparatide meets the Phase 3 CALYPSO primary endpoint in chronic hypoparathyroidism with full data presented at the European Congress of Endocrinology, Alkermes' LUMRYZ meets its primary endpoint in the Phase 3 REVITALYZ trial for idiopathic...
First Alzheimer’s Biomarker Reversal Linked to Lyme Disease Treatment
Alzheimer’s disease (AD) represents a significant medical concern for all of us as we grow older, as the NIH has published that the average risk of dementia over 55 years old is now 42%. AD is presently affecting 6.9 million Americans aged 65 or older and is expected...
Experimental Alzheimer’s Pill Boosts the Brain’s Cleanup System
Wouldn’t life be easier if someone was there to keep on top of chores around the house? That’s the idea behind Anavex Life Sciences’ experimental, once-daily pill blarcamesine, which is being tested in patients in the early stages of Alzheimer’s disease. This drug...
From Kennels to Clinics: Translating Veterinary Research to Human Trials
The next operational lessons for early-stage clinical trials in humans might not come from pharma but from a cattle ranch in Nebraska. While human clinical research debates decentralized trials, adaptive protocols, novel technologies, and new approaches to oversight,...
MRI Study Links Inflammation in Brain Reward Centre to Depression Severity
New research suggests that inflammatory and microstructural changes in a key brain reward region may differ between chronic depression and acute depressive symptoms, offering fresh insight into the biological mechanisms underlying the condition. In a large scale...
Functional Gut Clinic Launches GI Clinical Trials Division
The Functional Gut Clinic (FGC), the UK’s leading provider of specialist gastrointestinal (GI) diagnostics, today announced the launch of its dedicated GI Clinical Trials establishing the organisation as the country’s first boutique, end‑to‑end clinical research...
Pharvaris Announces Positive Phase 3 Results for Deucrictibant
Pharvaris Announces Positive Phase 3 Results for Deucrictibant as On Demand HAE Treatment Pharvaris has announced positive topline data from its global Phase 3 RAPIDe 3 study, confirming that the oral bradykinin B2 receptor antagonist deucrictibant shows strong...
Otsuka Wins Approval for Novel Rare Kidney Drug
Otsuka Gains Approval for First of Its Kind Treatment Against Rare Kidney Disease In a significant milestone for kidney disease care, Otsuka Pharmaceutical has received accelerated approval from the US Food and Drug Administration for a new therapy for Immunoglobulin...
New Hope for Patients with Hereditary Hemorrhagic Telangiectasia
Engasertib Trial Offers New Hope for Patients with Hereditary Hemorrhagic Telangiectasia A recent clinical study has delivered encouraging results for people living with hereditary hemorrhagic telangiectasia, a rare genetic vascular disorder that causes chronic and...
ALS- Clinical Signals of a “Synaptic Regenerative” Approach!
Pharmaceutical approaches to ALS remain sparse and "hard-to-develop". Riluzole (approved 1995) and edaravone (IV in 2017, oral in 2022) only offer modest benefits. More recently, Biogen's Qalsody (tofersen) was approved for SOD1-mutant ALS. But a new wave of new...
Ground-Breaking Gene Therapy for Hunter Syndrome
Miraculous Progress for 3-Year-Old After Ground-Breaking Gene Therapy for Hunter Syndrome A three-year-old boy, Oliver Chu, has astounded doctors after becoming the first person in the world with Hunter syndrome also called MPS II to receive a pioneering gene therapy....
The Future of Clinical Trials: Virtual, Decentralised, and Patient-Led
Clinical trials have long been the backbone of medical innovation, providing the evidence base for new treatments, diagnostics, and preventive measures. Yet for decades, the traditional model, site-based, paper-driven, and geographically limited, has been plagued by...
US Scientists Create Human Embryos from Skin Cells
In a ground breaking advance in reproductive biology, researchers in the United States have for the first time created early-stage human embryos by converting DNA from skin cells into functional eggs and then fertilising them with sperm. Though still at an...
Stem Cell Breakthrough: Woman Reverses Type 1 Diabetes Using Her Own Cells
In a pioneering medical achievement, a 25-year-old woman in China has become the first person in the world to reverse Type 1 diabetes using stem cells derived from her own body. The groundbreaking study, published in Cell in September 2024, marks a turning point in...







